MNPR
MNPR
NASDAQ · Biotechnology

Monopar Therapeutics Inc

$55.21
-3.46 (-5.90%)
As of Mar 22, 10:25 PM ET ·
Analyst Consensus
Strong Buy
20
Analysts
High
Coverage
Buy 19 95%
Hold 1 5%
Sell 0 0%
Price Target
Analyst Price Target -25.2% upside
Low Target $22.89
Average Target $41.31
High Target $45.20
Current Price $55.21
Current
$55.21
Target
$41.31
$22.89 $41.31 avg $45.20
Scenario Analysis
Bear Case
$22.89
-58.5%
Low target
Base Case
$41.31
-25.2%
Avg target
Bull Case
$45.20
+-18.1%
High target
Risk/Reward
0.3x
Unfavorable
Price in Context
52-Week High
$105.00
-47.4% from high
52-Week Low
$26.06
+111.9% from low
Target vs 52W High
$41.31
-60.7% vs high
Next Earnings Report
Mar 30, 2026 · After Market Close
3d
until earnings
EPS Est: $-0.50
Earnings in 3 days. Analyst targets may shift significantly after the report.
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Buy 39 69% $257.58 +24.3%
AMGN
Amgen Inc
Hold 42 50% $190.87 -46.1%
GILD
Gilead Sciences Inc
Strong Buy 37 81% $362.68 +162.3%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 79% $438.34 -3.7%
REGN
Regeneron Pharmaceuticals
Strong Buy 36 75% $76.80 -89.8%
ALNY
Alnylam Pharmaceuticals Inc
Strong Buy 36 78% $102.31 -68.9%
INSM
Insmed Inc
Strong Buy 26 92% $143.40 -3.3%
NTRA
Natera Inc
Strong Buy 27 89% $142.91 -27.6%